


BEST AVAILABLE COPY

GNE.3030R1C6

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant	: Goddard et al. (as amended)
Appl. No.	: 10/036,063
Filed	: December 26, 2001
For	: ANTIBODIES TO POLYPEPTIDES THAT INDUCE CELL PROLIFERATION (as amended)
Examiner	: Kolker, Daniel E.
Group Art Unit	: 1646

DECLARATION UNDER 37 CFR §1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We declare and state as follows:

1. We are the inventors of the invention claimed in the above-captioned patent application.
2. During the time period in which we participated in the events and activities described herein, we were employed by Genentech, Inc., the assignee of the above-captioned application.
3. All of the events and activities described herein were performed by us personally, or by others at our direction as part of our duties as employees of Genentech, Inc.
4. The invention claimed in the above-captioned patent application was conceived and reduced to practice in the United States prior to November 18, 1999 as described below.
5. Prior to November 18, 1999, we conceived of the invention claimed in the above-captioned patent application. This is demonstrated by the attached sequence printout (Exhibit A), which was generated prior to November 18, 1999, and which shows the complete sequence of the nucleic acid having the sequence of SEQ ID NO: 56. The attached printout also shows the complete sequence of the polypeptide which has the sequence of SEQ ID NO: 57. As evidenced by the sequence printout, we were in possession of the complete nucleic acid and amino acid sequences prior to November 18, 1999.
6. The date deleted from Exhibit A is prior to November 18, 1999. This date was redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.
7. After these initial experiments, we diligently reduced the claimed subject matter to practice by working to express and purify the encoded polypeptide and to run it systematically through many assays. The cDNA was deposited with the American Type Culture Collection (ATCC) on April 20, 1999 and assigned ATCC no. 203948. The protein of interest was assigned a "protein inventory

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.


8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: 
Audrey Goddard

Date: June 7/05

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: 5/31/05

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____ Date: _____
Audrey Goddard

By: _____ Date: _____
Paul J. Godowski

By: _____ Date: 6/8/05
Austin L. Gurney

By: _____ Date: _____
James Pan

By: _____ Date: _____
Colin K. Watanabe

By: _____ Date: _____
William I. Wood

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard


Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan 

Date: June 9/05

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: Colin K. Watanabe
Colin K. Watanabe

Date: 6/8/2005

By: _____
William I. Wood

Date: _____

Appl. No. : 10/036,063
Filed : December 26, 2001

number" (e.g., PIN1205-1), and this protein is a polypeptide having the sequence of SEQ ID NO:57, and is encoded by SEQ ID NO: 56.

8. Exhibit B shows that the protein lot designated PIN1205-1 was delivered to James Pan on a date prior to November 18, 1999 in order to perform assay ASY92, called "Mouse Mesangial Cell proliferation Assay." Also, as shown in Exhibit B, the assay was completed on a date prior to November 18, 1999. Exhibit B also shows that the tested polypeptides tested positive ("All Positives"), thereby confirming the ability of the encoded polypeptide to induce mesangial cell proliferation. Thus, actual reduction to practice occurred on a date prior to November 18, 1999.

9. The dates deleted from Exhibit B all are prior to November 18, 1999. These dates were redacted pursuant to M.P.E.P. § 715.07. The date that remains is the date the report was printed, April 28, 2005.

10. We worked with the Genentech, Inc. patent department to prepare a provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, and described how to make and use antibodies to the sequences of SEQ ID NO:57. That application was filed on April 21, 1999 as U.S. Provisional Application No. 60/130,359.

11. After reducing the invention to practice, we worked with the Genentech, Inc. patent department to prepare a non-provisional patent application, which included the sequences of SEQ ID NO:56 and SEQ ID NO:57, as well as the data showing the ability to induce mesangial cell proliferation. That application was filed on March 1, 2000 as PCT/US00/05601.

11. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

By: _____
Audrey Goddard

Date: _____

By: _____
Paul J. Godowski

Date: _____

By: _____
Austin L. Gurney

Date: _____

By: _____
James Pan

Date: _____

By: _____
Colin K. Watanabe

Date: _____

By: _____
William I. Wood

Date: 5/27/05

EXHIBIT A

GENEX GENES

Find G: New G: Update

ASX ... 92 92 92

Additional Resources:

ASY92

Assay Name	Mouse Mesangial Cell proliferation Assay		
Alias Name	Mu Mes Cell Prolf		
Status	Retired		
Class	Primary		
Format	96 Well		
Type	Cell		
Sample Requirements			
Assay Volume	0.1 ml		
Fold Dil Into Well	10 Fold		
Replicates	3		
Dilutions	2		
Volume Requested	0.03ml/well/conc		
Protocol			
Species	Mouse		
Purpose	Screen SPDI proteins which can stimulate Mesangial Cell Proliferation		
Protocol	On day 1: Mouse mesangial cells are plated on a 96 well plate in Media[A 3:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 medium- 95% fetal bovine serum-5% supplemented with 14mM hepes] and gw overnight. On day 2: SPDI Proteins are diluted at 2 conc. [1%- 0.1%] in serum-free Media and added to the cells. On day 4: After 48 hours incubation- each well of the plate was added 20 µl of the Cell Titer 96 Aqueous one solution reagent [Promega] and colorimetric reaction was allowed for 2 hours. The absorbance [OD] is measured at 490 nm.		
Matrix	Promega kit for the assay-		
Result Calculation	replicated average		
Result Interpretation	Any PIN that gives an absorbance reading which is 15% above the media control is considered a hit.		
Result Cutoff	> 15 %		
In Vivo: In Vitro:			
Comments			
Status	Retired		
Date Entered			
Date Cancelled			
Department	Endocrinology		
Scientist	James (Guohua) Pan		
Notebook	0		
Assays			
Cancel Reason	Bioarea		
Lab Scientist	Wenguang Nao		

ASX | DNA | DOM | EXG | FAM | ELS | LIB | LOT | MAP | OLI | PBB | PRO | PUR | RNA | SRC | UNG | XPT | YST
ASX | FAM | EXG | FAM | ELS | LIB | LOT | MAP | OLI | PBB | PRO | PUR | RNA | SRC | UNG | XPT | YST

GenmGenus Feedback

GENEALOGIES

SEARCH

Find C New C Update

SELECT

GENEALOGIES

SEARCH

Find C New C Update

SELECT

SPDI Assays

Assay Viewer

- ASY11 Heart Neonatal Hypertrophy
- ASY12 Heart Adult Hypertrophy
- ASY13 Adipocyte Lipolysis
- ASY14 Adipocyte Lipogenesis
- ASY15 Hematopoietic stem cell proliferation
- ASY16 Hippocampal Neuron Survival
- ASY17 Renal Neuron Survival (5-6 days culture)
- ASY18 Endothelial cell proliferation
- ASY19 Inhibition of VEGF-stimulated endothelial
- ASY110 Endothelial cell migration (production of)
- ASY111 B cell IgE synthesis inhibition

Find Lots

- All PIN
- All DNA

Show Lots for:

PIN: 1205

Number: 1205

☐ Include UNQ Related Lots

Lots for Search

PIN1205-1

☐ All Positives ☐ Verified Positives ☐ Pending

Date Complete From

To

ASSAY RESULT LIST

ASY	ASY Name	PUR/EXP/DNA	LOT	LOT Name	Pos	Verified	Conc	Conc Unit	Mean	Crit	UNQ	Protein Name	Comment
ASY02	Mu Mess Cell Prolif	PUR1715	LOT7447	PIN1205-1			0.10	%	1		UNQ1915	Human DPKL1915 IgG	
ASY02	Mu Mess Cell Prolif	PUR1715	LOT7447	PIN1205-1			1.00	%	1		UNQ1915	Human DPKL1915 IgG	

ASY | DNA | DOM | EXE | EAM | ELS | LB | LOT | MAP | OMI | PER | PTO | PUR | RNA | SER | UNQ | XET | XSI
Assay Viewer | Sequence Viewer | Gene Viewer | Genom2Genes | SAGE

Genom2Genes Feedback

EXHIBIT B

>Thursday, April 28, 2005

>DNA92234 [Full]

>887 Sites [All Sites]

> [DNA92234], sheldens

> Lib309

>Sequence confirmed by phredphrap

```

      thai
      nlaiII  snaBI
      sphI   fnuDII/mvnI
      nspHI  bstUI taiI      mnII
      taiI  nspI  bsh1236I   taqI
      maeII/hpyCH4IV bsiWI/splI xhoI
      aluI  hinII/acyI cac8I  bsaAI   tsp509I[M.ecoRI-]
      sapI  ahaII/bsaHI  mlui  rsaI   ecoRI  tliI
      maeIII mboII      aatII  cac8I  aflIII maeII/hpyCH4IV hpy188I  smII
      hpyI   sfcI  earI/ksp632I hpy99I hpyCH4V csp6I  aluI  apoI  paer7I   hpy188I aciI   bpmI/g
      1 TAGGTGACAC TATAGAAGAG CTATGACGTC GCATGCACGC GTACGTAAGC TCGGAATTGC TCGCGAGGAA TGAATACCTC CGAAGCCGCT TTGTTCTCCA
      ATCCACTGTG ATATCTTCTC GATACTGCAG CGTACGTCG CATGCATTGC AGCCTTAAGC CGAGCTCCTT ACTTATGGAG GCTTCGGCGA AACAAAGAGT
      ^insert starts here
```

```

scrFI[M.hpaII-]
nciI
mspi
hpall
dsav
bpuAI bssKI bsp1286
bbsI bsII bsmFI taiI bmyI
alul mnlI mboII bsauI maeII/hpyCH4IV mseI maeIII nla
101 GATGTGATA GCTCCACTAT ACCAGCCTCG TCTTCCTTCC GGGGGACAAC GTGGGTCAGG GCACAGAGAG ATATTAAAG TCACCCCTCTT GGGGCTTTCA
CTACACTTAT CGAGGTGATA TGGTCGGAGC AGAAGGAAGG CCCCCTGTG CACCAGTCC CGTGTCTCTC TATAAATTAC AGTGGGAGAA CCCCAGAAAGT

sau3AI
mboI/ndeII[dam-]
dpmII[dam-]
dpmI[dam+]
alwI[dam-]
nlaIV
pleI mnlI bstYI/xhoII hgaI
mlyI rmaI bamHI bsII tseI
hinFI maeI hpy188I bstXI alwI[dam-] hpy188III fnu4HI/bso
bsmFI mnlI bfaI eco57I bpmI/gsuI[dcn-] bsII avaI bbvI bsmFI
201 TGGGACTCCC TCTGCCACAT TTTTGGAGG TTGGGAAGT TGCTAGAGGC TTCAGACTC CAGCCTAATG GATCCCCAAC TCGGAGAAAT GGCTGCGTCC
ACCCTGAGGG AGACGGTGTA AAAAACCTCC AACATCTCCG AAGTCTTGAG GTGGATTAC CTAGGGTTTG AGCCCTCTTA CCGACGCAGG
1 M D P K L G R M A A S
^MET

```

```

fnu4HI/bsoFI
tseI      aciI
tseI mwoI    thai nlaIII      haeII
mwoI   fnu4HI/bsoFI nspHI      mspI
fnu4HI/bsoFI   fnuDII/mvni      scrFI[M.hpall-]
bbvI   bbvI   bstUI[M.hhaI-]    nciI
tseI tseI     bsh1236I          dsav hinPI      bpuaI      ms
mwoI   fnu4HI/bsoFI hinPI nspI   hphI      mwoI hpall      bbsI      rsal      mnlI
fnu4HI/bsoFI   hhaI/cfoI      mnlI      aciI bssKI      xmnI mboII      csp6I      ecoNI
cac8I   bbvI   bpmI/gsuI[dcM-]   bseRI      mnlI bslI bsaJI hhaI/cfoI   asp700      bsrI      bslI
301 CTGCTGGCTG TGCTGCTGCT GCTGCTGGAG CGCGGCATGT TCTCTCACC CTCCCCGCC CCGCGCTGT TAGAGAAAGT CTTCCAGTAC ATTGACCTCC
GACGACCGAC ACGACGACGA CGACGACCTC GCGCCCTACA AGAGGAGTGG GAGGGCGGG GCGCGCGACA ATCTCTTTCA GAAGTCATG TAACTGGAGG
12 L L A V L L L L L E R G M F S S P S P P P A L L E K V F Q Y I D L H

mboII
earI/ksp632I
sapi
aluI
sstI
sacI
tth111I/aspi
pleI
pflFI
haeIII/palI
mscI/balI
eaeI   taqI   hinfI
cfrI   hpy188III
bsgi   hgaI   eco57I
apoi   alwNI[dcM-]   haeIII/palI   mscI/balI   eaeI   taqI   hinfI   cfrI   hpy188III
foki   tsp509I   alw26I/bsmAI   mscI/balI   eaeI   taqI   hinfI   cfrI   hpy188III
bstF5I   hpyCH4V   bsgi   hgaI   eco57I
hpy188III   bsgi   hgaI   eco57I   mnlI   eco57I   bmyI   eco57I   ea
401 ATCAGGATGA ATTTGTGCAG ACGCTGAAGG AGTGGGTGGC CATCGAGAGC GACTCTGTCC AGCCTGTGCC TCGCTTCAGA CAAGAGCTCT TCAGAATGAT
TAGTCTACT TAAACACGTC TCGGACTTCC TCACCCACCG GTAGCTCTCG CTGAGACAGG TCGGACACGG AGCGAAGTCT GTTCTCGAGA AGTCTTACTA
46 Q D E F V Q T L K E W V A I E S D S V Q P V P R F R Q E L F R M M

```

```

mwoI
scrFI[dcM-]
pspGI sau96I[M.haeIII-]
mvaI pspOMI/bsp120I
ecoRII[dcM-]
dsaV[dcM-]
bstNI nlaIV
bssKI[dcM-]
hinPI bsp1286[M.haeIII-]
hhaI/cfoI sfiI
tseI bsaJI bmyI
fnu4HI/bsoFI sau96I[M.haeIII-]
bbvI apyI[dcM+]
dsaI tseI hpyCH4V banII[M.haeIII-]
btgI/bstDSI sfcI haeII apaI mnli
bsaJI aciI tseI alwNI[dcM-] haeII/pali bsaJI
mwoI fnu4HI/bsoFI pstI[M.H1-] nlaIV haeIII/pali
bceAI bbvI fnu4HI/bsoFI ecoO109I/draII nlaII mnli bbvI
haeIII/pali bbvI alw26I/bsmAI bgli[M.haeII-] pshAI avaII alw26I/bsmAI hpy188I mnli
501 GGCCTGGCT GCGGACACGC TGCAGCGCCT GGGGGCCCGT GTGGCTCGG TGGACATGGG TCCTCAGCAG CTGCCCCGATG GTCAGAGTCT TCCAATACCT
CCGGCACCGA CGCCTGTGG ACCTGTGGG CACCGGAGCC ACCGTATCCC AGGAGTCGTC GACGGGCTAC CAGTCTCAGA AGTTATGGA
79 A V A A D T L Q R L G A R V A S V D M G P Q Q L P D G Q S L P I P

```

```

    eaeI[dcM-]
    scrFI[dcM-]
    pspGI
    mvaI
    ecorII[dcM-]
    dsaV[dcM-]
    bstNI bslI
    bssKI[dcM-]
    apyI[dcM+]
    foki cfrI bsrI
    bstF5I haeIII/palI
    601 CCCGTCATCC TGGCCGAAC TGGGAGCGAT CCCACGAAAG GCACCGTGTG CTTCTACGGC CACTTGGACG TGCAGCCTGC TGACCGGGGC GATGGGTGGC
    GGCAGTAGG ACCGGCTTGA CCCCTCGCTA GGGTGCTTC CGTGGCACAC GAAGATGCCG GTGAACCTGC ACGTCGGACG ACTGGCCCCG CTACCCACCG
    112 P V I L A E L G S D P T K G T V C F Y G H L D V Q P A D R G D G W L

    sau96I
    nlaIV
    avall
    701 TCACGGACCC CTATGTGCTG ACGGAGGTAG ACGGGAAC TTAGGACGA GGAGCGACG ACAACAAAGG CCTGTCTTG GCTTGATCA ATGCTGTGAG
    AGTGCCTGGG GATACACGAC TGCCTCCATC TGCCTTTGA AATACCTGCT CCTCGCTGC TGTGTTTCC GGCACAGAAC CGAACCTAGT TACGACACTC
    146 T D P Y V L T E V D G K L Y G R G A T D N K G P V L A W I N A V S

    sau3AI mwoI
    bslI
    sau96I[M.haeIII-]
    haeIII/palI
    haeIII/palI
    ecoO109I/draII
    601 TCACGGACCC CTATGTGCTG ACGGAGGTAG ACGGGAAC TTAGGACGA GGAGCGACG ACAACAAAGG CCTGTCTTG GCTTGATCA ATGCTGTGAG
    AGTGCCTGGG GATACACGAC TGCCTCCATC TGCCTTTGA AATACCTGCT CCTCGCTGC TGTGTTTCC GGCACAGAAC CGAACCTAGT TACGACACTC
    146 T D P Y V L T E V D G K L Y G R G A T D N K G P V L A W I N A V S

```



```

scrFI[dcM-]      mnlI
pspGI            bpmI/gsuI[dcM-]
mvaI             sau3AI
ecoRII[dcM-]     pspGI
dsav[dcM-] mboI/ndeII[dam-] mvaI
bstNI            dpnII[dam-] ecoRII[dcM-]
bsp1286          bstYI/xhoII dsav[dcM-]
bmyI bssKI[dcM-] mboII bstNI
hpy188I apyI[dcM+] dpnI[dam+] bssKI[dcM-]
eco57I bsaJI    bglII   apyI[dcM+]
nwoI banII bpmI/gsuI[dcM-] bsaJI
801 CGCCTTCAGA GCCCTGGAGC AGATCTTCC TGTGAATATC AAATTCATCA TTGAGGGGAT GGAAGAGGCT GGCTCTGTG CCCTGGAGGA ACTTGTGGAA
    GCGGAAGTCT CCGGACCTCG TTCTAGAAGG ACACTTATAG TTTAAGTAGT AACTCCCCCTA CCTTCTCCGA CCGAGACACAC GGGACCTCT TGAACACCTT
179 A F R A L E Q D L P V N I K F I I E G M E E A G S V A L E E L V E

```

```

scrFI[
ncII
mspI
hpaII
dsav
bssKI
bsaJI
xmaI/ps
smaI
scrFI[M
ncII
dsav
bssKI
bsaJI
avaI[M.
nlaIV
sau3AI
mboI/ndeII[dam-]
dpnII[dam-]
dpnI[dam+]
alwI[dam-]
cac8I
hpy188I
tsp509I
tfII
sau96I mboII
avaII hinFI
901 AAAGAAAAGG ACCGATTCTT CTCTGGTGTG GACTACATTG TAATTTTCAGA TAACCTGTGG ATCAGCCAAA GGAAGCCAGC AATCACTTAT GGAACCCGGG
TTTCTTTTCC TGGCTAAGAA GAGACCACAC CTGATGTAAC ATTAAGTCT ATTGGACACC TAGTCGGTTT CCTTCGGTCG TTAGTGAATA CCTTGGGCCC
212 K E K D R F F S G V D Y I V I S D N L W I S Q R K P A I T Y G T R G

```



```

scrFI[dcn-]
pspGI
mvaI
ecorII[dcn-]
dsaV[dcn-]
bstNI
bssKI[dcn-]
sau96I[dcn-]
nlaIV
avaII[dcn-]
scrFI[dcn-]
pspGI apyI[dcn+]
mvaI bsmFI
ecorII[dcn-]
dsaV[dcn-]
bstNI bsaJI
bssKI[dcn-] tfII
apyI[dcn+] hinfI
mboII
1101 TCTTCTCGGT AGCTGGTAG ACTCGTCTGG TCATATCCTG GTCCCTGGAA TCTATGATGA AGTGGTTCCT CTTACAGAAG AGGAAATATAA TACATACAAA
AGAAGAGCCA TCGGACCATC TGAGCAGACC AGTATAGGAC CAGGGACCTT AGATACTACT TCACCAAGGA GAATGTCTTC TCCTTTATTT ATGTATGTTT
279 L L G S L V D S S G H I L V P G I Y D E V V P L T E E E I N T Y K

```

```

rsal
csp6I
nlaIV
kpnI
bani
asp718
bpmI/gsuI[dcM]
hpy188III
acc65I
mnII
hpyCH4V
mnII
AATGCACCTC TGGAGGTACC
CGGTAGGTAG ATCTGGATCT TCTATGGCC TTATCGTCGG CCCAACTCTT TAAAGACAAG CTATGATTCC TCCTCTAAGA TTACGTGGAG ACCTCCATGG
312 A I H L D L E E Y R N S S R V E K F L F D T K E E I L M H L W R Y P

scrFI[M.hpaiI-]
nciI
mspi
hpaiI
dsav
bssKI
tseI
fokI hpy188III mboII hpaiI fnu4HI/bsoFI tsp509I
bstF5I bfaI bsaWI bbsWI apoI taqI ddeI bseRI hinfI hpyCH4V
1201 GCCATCCATC TAGACCTAGA AGAATACCGG AATAGCAGCC GGGTTGAGAA ATTCTCTGTC GATACTAAGG AGGAGATTCT AATGCACCTC TGGAGGTACC
CGGTAGGTAG ATCTGGATCT TCTATGGCC TTATCGTCGG CCCAACTCTT TAAAGACAAG CTATGATTCC TCCTCTAAGA TTACGTGGAG ACCTCCATGG
312 A I H L D L E E Y R N S S R V E K F L F D T K E E I L M H L W R Y P

haeIII/paiI
eaeI[dcM-]
cfrI
thaI
fnuBII/mvni scrFI[dcM-]
pspGI
mvaI
ecoRII[dcM-]
dsav[dcM-]
bstNI
bssKI[dcM-]
apyI[dcM+]
xnnI
asp700
bfaI
bsm
tsp509I
apoI
rmaI
maei
nlaIII taqI[dam-]
bst4CI/hpyCH4III
1301 CATCTCTTTC TATTCATGG ATCGAGGGCG CGTTTGATGA GCCTGGAAC TACCTGGCCG AGTTATAGGA AAATTTTCAA TCCGTCTAGT
GTAGAGAAAG ATAAGTACCC TAGCTCCCGC GCAAACTACT CGGACCTTGA TTTTGTCAGT ATGGACCGGC TCAATATCCT TTAAAAAGTT AGGCAGATCA
346 S L S I H G I E G A F D E P G T K T V I P G R V I G K F S I R L V

rmaI
maei
xbaI
fokI hpy188III mboII hpaiI fnu4HI/bsoFI tsp509I
bstF5I bfaI bsaWI bbsWI apoI taqI ddeI bseRI hinfI hpyCH4V
1201 GCCATCCATC TAGACCTAGA AGAATACCGG AATAGCAGCC GGGTTGAGAA ATTCTCTGTC GATACTAAGG AGGAGATTCT AATGCACCTC TGGAGGTACC
CGGTAGGTAG ATCTGGATCT TCTATGGCC TTATCGTCGG CCCAACTCTT TAAAGACAAG CTATGATTCC TCCTCTAAGA TTACGTGGAG ACCTCCATGG
312 A I H L D L E E Y R N S S R V E K F L F D T K E E I L M H L W R Y P

haeIII/paiI
eaeI[dcM-]
cfrI
thaI
fnuBII/mvni scrFI[dcM-]
pspGI
mvaI
ecoRII[dcM-]
dsav[dcM-]
bstNI
bssKI[dcM-]
apyI[dcM+]
xnnI
asp700
bfaI
bsm
tsp509I
apoI
rmaI
maei
nlaIII taqI[dam-]
bst4CI/hpyCH4III
1301 CATCTCTTTC TATTCATGG ATCGAGGGCG CGTTTGATGA GCCTGGAAC TACCTGGCCG AGTTATAGGA AAATTTTCAA TCCGTCTAGT
GTAGAGAAAG ATAAGTACCC TAGCTCCCGC GCAAACTACT CGGACCTTGA TTTTGTCAGT ATGGACCGGC TCAATATCCT TTAAAAAGTT AGGCAGATCA
346 S L S I H G I E G A F D E P G T K T V I P G R V I G K F S I R L V

```

[illegible]

```

sau3AI
mboI/ndeII[dam-]
dpnII[dam-]
fokI dpnI[dam+]
bstF5I
scrFI[M.hpaII-]
ncII alwI[dam-]
mspi nlaIV
hpaII bstYI/xhoII
dsav bamHI
bsSKI alwI[dam-] muni/mfeI
tsp509I
1601 TCCGGGATGG ATCCACCATT CCAATTGCCA AAATGTTCCA GGAGATCGTC CACAAGAGCG TGGTGCTAAT TCCGCTGGGA GCTGTTGATG ATGGAGAACA
AGGCCTACC TAGGTGGTAA GGTTAACGGT TTACAAGGT CCTCTAGCAG GTGTTCTCGC ACCACGATTA AGCGGACCCT CGACAACCTAC TACCTCTTGT
446 R D G S T I P I A K M F Q E I V H K S V V L I P L G A V D D G E H

sau3AI
scrFI[dcn-]
pspGI mboI/ndeII[dam-]
nvaI dpnII[dam-]
ecorII[dcn-]
dsav[dcn-]
bstNI dpnI[dam+]
bsSKI[dcn-]
tsp509I
mwoI acII aluI
mspAII/nspBII
nlaIV
tseI
fnu4HI/bsoFI
sau96I[M.haeIII-]
mnII
tsp509I bbvI
ddeI
haeIII/palI aseI/asnI/vspI
1701 TTCGCAGAAT GAGAAAATCA ACAGGTGGAA CTACATAGAG GGAACCAAT TATTGCTGC CTTTTCCTTA GAGATGGCCC AGCTCCATTA ATCACAAGAA
AAGCGTCTTA CTCCTTTAGT TGTCACCTT GATGTATCTC CCTTGCTTA ATAAACGACG GAAAAAGAAT CTCTACCGGG TCGAGGTAAT TAGTGTCTT
479 S Q N E K I N R W N Y I E G T K L F A A F F L E M A Q L H O

tru9I
aluI mseI

```

```

sau3AI
mboI/ndeII[dam-]
dpnII[dam-]
dpnI[dam+]
    hpy188I
sau3AI    tspRI
    hpy188I    alwI[dam-]
        rmaI    mboI/ndeII[dam-]    hphI
        maeI    dpnII[dam-]    tfiI    mnlI    foki    bfaI    foki    bstF5I    hpy188III    apoI    maeI    rsaI
        bfaI    dpnI[dam+]    hinfi[M.hphI-]    bstF5I    bstF5I    hpy188III    bfaI    csp6I
1801 CCTTCTAGTC TGATCTGATC CACTGACAGA TTCACCTCCC CCACATCCCT AGACAGGGAT GGAATGTAAA TATCCAGAGA ATTTGGGTCT AGTATAGTAC
GGAAGATCAG ACTAGACTAG GTGACTGTCT AAGTGGAGGG GGTGTAGGGA TCTGTCCCTA CCTTACATTT ATAGGTCTCT TAAACCCAGA TCATATCATG

sau96I
sau3AI
    mboI/ndeII[dam-]
    dpnII[dam-]
    dpnI[dam+]
        hpy188III
        mseI
        ahaIII/draI    ecoRV    alwI[dam-]    sspI
1901 ATTTTCCCCTT CCATTAAAA TGCTTGGGA TATCTGGATC AGTAATAAAA TATTCAAAG GCACAGATGT TGAATGTTT TTAAGGTCCC CCCTGCACA
TAAAGGGAA GGTAAATTTT ACAGAACCTT ATAGACCTAG TCATTATTTT ATAAAGTTTC CGTGTCTACA ACCTTTACCA AATCCAGGG GGTGACGTGT

```



```

scrFI[dcM-]
pspGI
mvaI
ecoRII[dcM-]
dsav[dcM-]
bstNI
tseI
cac8I
tseI fnu4HI/bsoFI
fnu4HI/bsoFI
smLI bbvI
mnlI aluI hpyCH4V
2001 CCTTCTCAA GTCATAGCTG CTTGACGCAA CTTGATTTCC CCAAGTCCTG TGCATAGCC CCAGGATTGG ATTCCTTCCA ACCTTTTAGC ATATCTCCAA
GGAAGGAGTT CAGTATCGAC GAACGTCCGT GAACATAAGG GGTTCAGGAC ACGTTATCGG GGTCTTAACC TAAGGAAGGT TGAATAATCG TATAGAGGTT
sau96I tsp45I
avaII bssSI
ppuMI hgiAI/aspHI
ecoO109I/draII hpy188III
mspI rmaI bsp1286
tsp509I hpaII maeI smLI bsiHKA1 foki
hpyCH4V bsaWI bfaI mnlI bmyI maeIII bstE5I
2101 CCTTGCAATT TGATTGSCAT AATCACTCCG GTTTGCTTTC TAGGTCCTCA AGTGCTCGTG ACACATAATC ATTCATCCA ATGATCGCCT TTGCTTTACC
GGAACGTTAA ACTAACCGTA TTAGTGAGGC CAAACGAAAG ATCCAGGAGT TCACGAGCAC TGTGTATTAG TAAGGTAGGT TACTAGCGGA AACGAAATGG
tru9I
mseI bsmAI
aseI/asnI/vspI bsaI tspRI
2201 ACTCTTTTCT TTTATCTTAT TAATAAAAAT GTTGGTCTCC ACCACTGNCT CCCAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA
TGAGAAAAGGA AAATAGAATA ATTAATTTTA CAACCAAGAGG TGTGCACNGA GGGTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT

```

```

scrFI[M.hpaII-]
ncII
mspI
hpaII
dsav
bssKI      sau96I rsal
xmaI/pspAI  rsrII/cspI
smaI      mroI   nlaIV
          scrFI[M.hpaII-] cpoI kpnI hpyCH4V
          taqI nciI   hpy188III csp6I
          sstI salI dsav bspMII bani sfcI
          sacI hincII/hindII[M.taqI-] avalI[M.hpaII-]
          eagI/xmaIII/eclXI aluI accI[M.taqI-] tru9I mspI asp718
          eaeI      hgiAI/aspHI[M.aluI-] mseI bspEI cfr10I/bsrFI
          cfrI      rmaI   ecl136II bssKI aseI/asnI/vspI acc65I cac8I
          bsiEI      maeI bsp1286[M.aluI-] xmnI tsp509I bsaWI pstI
          notI      bfaI bsiHKAI bsaJI tsp509I bsaWI ageI sse8387I
          fnu4HI/bsoFI bmyI hpy99I auaI[M.hpaII-] hpaII mspI bspMI rsal
          aciI      speI banII[M.aluI-] asp700 accIII hpaII sbfI csp6I aluI sf
          2301 AAAAAAAAAA AAAGGCGGC CGCCGACTAG TGAGTCGTC GACCCGGGAA TTAATTCGG ACCGGTACCT GCAGGCGTAC CAGCTTTCCC
              TTTTCTTTT TTTTCTTTT TTTCTGATC ACTCGAGCAG CTGGGCCCTT AATTAAGGCC TGCCCATGGA CGTCCGATG GTCGAAAGGG

```

```

pleI
mlyI
hinfI      aluI
2401 TATAGTCAGT CGTATTAGAG CTTGG
    ATATCACTCA GCATAATCTC GAACC

```

> length: 2425

aatII (GACGTC) :	25
acc65I (GGTACC) :	1295 2374
accI (GTMKAC) :	727 1117 2348
accIII (TCCGGA) :	2366
aciI (CCGC) :	86 332 355 511 1420 1672 2326 2330
acyI (GRCGYC) :	25
afIIII (ACRYGT) :	37
ageI (ACCGGT) :	2371
ahaII (GRCGYC) :	25
ahaIII (TTAAA) :	1914
aluI (AGCT) :	19 48 110 485 569 1006 1680 1781 2016 2343 2392 2419
alw26I (CAGNNCTG) :	418 523 565
alwI (GGATCNNNN) :	270 271 628 785 959 1319 1599 1609 1610 1817 1936
alwNI (CAGNNCTG) :	418 523 565
apaI (GGGCCC) :	533
apoI (RAATTY) :	54 409 841 1249 1381 1879
apyI (CCWGG) :	528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
aseI (ATTAAT) :	1787 2219 2360
asnI (ATTAAT) :	1787 2219 2360
asp700 (GAANNNTTC) :	375 1159 1379 1469 2358
asp718 (GGTACC) :	1295 2374
asphi (GWGWC) :	484 2152 2342
aspl (GACNNNGTC) :	451
avaI (CYCGRG) :	62 280 995 2353
avaII (GGWCC) :	559 705 909 1140 1985 2143 2369
balI (TGGCCA) :	437
banHI (GGATCC) :	270 1609
banI (GGYRCC) :	640 1295 2374

banII (GRGCTC) :	484 533 809 2342
bbsI (GAAGACNNNNN) :	130 379 587
bbvI (GCAGC) :	292 312 315 318 321 508 519 522 567 570 672 1235 1552 1756 2017 2024
bceAI (ACGGCNNNNNNNNNN) :	502 656
bfaI (CTAG) :	243 1210 1216 1396 1504 1805 1849 1889 2140 2337
bglI (GCCNNNNGGC) :	535
bglII (AGATCT) :	822
bmyI (GDGCHC) :	159 484 533 809 2152 2342
bpmI (CTGGAG) :	96 258 325 814 883 1290
bpuAI (GAAGACNNNNNN) :	130 379 587
bsaAI (YACGTR) :	42
bsaHI (GRCGYC) :	25
bsaI (GGTCTCNNNN) :	1034 2234
bsaJI (CCNNGG) :	139 359 503 528 545 684 812 881 995 996 1143 1516 2060 2353
bsaWI (WCCGGW) :	1226 2127 2366 2371
bseRI (GAGGAGNNNNNNNN) :	342 749 1270
bsgI (GTGCAG) :	415 670 1994
bsh1236I (CGCG) :	38 331 1329
bsiEI (CGRYCG) :	755 2327
bsiHKAI (GWGCWC) :	484 2152 2342
bsiWI (CGTACG) :	40
bslI (CCNNNNNNGG) :	135 184 274 275 354 396 614 631 771 1847 1848 2060
bsmA1 (GTCTC) :	1034 2235
bsmA1 (GTCTC) :	1034 2235
bsmFI (GGGACNNNNNNNNNN) :	143 202 297 1141 1399 1986
bsoFI (GCNGC) :	85 292 312 315 318 321 332 508 519 522 567 570 672 1235 1552 1756
	2017 2024 2326 2329
	533
bsp120I (GGGCCC) :	
bsp1286 (GDGCHC) :	159 484 533 809 2152 2342
bspCNI (CTCAGNNNNNNNNNN) :	563 1050

bspEI (TCCGGA) :	2366
bspHI (TCATGA) :	1074
bspMI (ACCTGC) :	2377
bspMII (TCCGGA) :	2366
bsrFI (RCCGGY) :	2371
bsrI (ACTGNN) :	384 618 1542
bssXI (CCNGG) :	139 360 528 609 684 813 882 995 996 1038 1113 1137 1144 1239 1342
	1363 1602 1638 2061 2353 2354
	2155
bssSI (CTCGTG) :	
bst4CI (ACNGT) :	643 1354 1573
bstAPI (GCANNNNTGCG) :	641
bstDSI (CCRYGG) :	503 1516
bstFSI (GGATG) :	405 606 857 1068 1203 1605 1844 1857 2175
bstNI (CCWGG) :	528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
bstUI (CGCG) :	38 331 1329
bstXI (CCANNNNNNTGG) :	260 1478
bstYI (RGATCY) :	270 822 1609
btgI (CCRYGG) :	503 1516
btrI (CACGTC) :	667
btsI (GCAGTGNN) :	1992
cac8I (GCNNGC) :	31 35 303 675 868 975 2020 2381
cfoI (GCGC) :	330 364 525 800 1328
cfr10I (RCCGGY) :	2371
cfrI (YGGCCR) :	437 500 611 657 1365 2327
cpoI (CGGWCCG) :	2368
csf6I (GTAC) :	41 387 1296 1897 2375 2387
cspI (CGGWCCG) :	2368
ddeI (CTNAG) :	563 1050 1265 1767
dpnI (GATC) :	271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937
	2183

dpnII (GATC): 271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937
 2183
 draI (TTTAAA): 1914
 draII (RGNCCY): 532 558 768 1984 2142
 draIII (CACNNNGTG): 642
 dsaI (CCRYGG): 503 1516
 dsaV (CCNGG): 139 360 528 609 684 813 882 995 996 1038 1113 1137 1144 1239 1342
 1363 1602 1638 2061 2353 2354
 437 500 611 657 1365 2327
 eaeI (YGGCCR): 2327
 eagI (CGGCCG): 15 487 862 1100 1177
 earI (CTCTTCNNNN): 484 2342
 ecl136II (GAGCTC): 2327
 eclXI (CGGCCG): 250 424 474 489 804
 eco57I (CTGAAG): 396
 ecoNI (CCTNNNNNAGG): 532 558 768 1984 2142
 ecoO109I (RGNCCY): 54
 ecoRI (GAATTC): 528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
 ecoRII (CCWGG): 1929
 ecoRV (GATATC): 85 292 312 315 318 321 332 508 519 522 567 570 672 1235 1552 1756
 fnu4HI (GCNGC): 2017 2024 2326 2329
 fnuDII (CGCG): 38 331 1329
 fokI (GGATG): 405 606 857 1068 1203 1605 1844 1857 2175
 gsuI (CTGGAG): 96 258 325 814 883 1290
 haeII (RGC GCY): 363 524 799
 haeIII (GGCC): 438 501 534 543 612 658 769 1366 1776 2328
 hgaI (GACGC): 295 420
 hgiAI (GWGCWC): 484 2152 2342
 hhaI (GCGC): 330 364 525 800 1328
 hinPI (GCGC): 330 364 525 800 1328

hincII (GTYRAC) :	2348
hindII (GTYRAC) :	2348
hinfI (GATC) :	204 451 585 914 1120 1148 1275 1500 1829 2070 2407
hinII (GRCGYC) :	25
hpaII (CCGG) :	139 361 684 996 1227 1239 1602 2128 2354 2367 2372
hphI (GGTGA) :	3 181 346 1023 1434 1832
hpy188I (TCNGA) :	51 79 252 476 491 582 806 946 1568 1809 1814
hpy188III (TCNNGA) :	97 281 402 443 1051 1074 1209 1289 1446 1873 1933 2156 2366
hpy99I (CGWCG) :	27 2347
hpyCH4III (ACNGT) :	643 1354 1573
hpyCH4IV (ACGT) :	26 43 149 668
hpyCH4V (TGCA) :	34 416 521 671 1030 1283 1524 1995 2023 2051 2104 2380
kpnI (GGTACC) :	1295 2374
ksp632I (CTCTTCNNNN) :	15 487 862 1100 1177
maeI (CTAG) :	243 1210 1216 1396 1504 1805 1849 1889 2140 2337
maeII (ACGT) :	26 43 149 668
maeIII (GTNAC) :	4 180 1435 2158
mboI (GATC) :	271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937 2183
mboII (GAAGA) :	15 131 380 488 588 825 862 917 1101 1177 1219 1450
mcrI (CGRYCG) :	755 2327
mfeI (CAATTG) :	1622
mluI (ACGCGT) :	37
mlvI (GAGTCNNNN) :	204 451 585 1120 1500 2407
mnI (CCTC) :	65 77 126 185 209 227 246 344 350 396 469 545 562 598 724 749 853 865 886 1021 1168 1180 1270 1287 1293 1324 1402 1738 1835 2005 2146
mroI (TCCGGA) :	2366
mscI (TGGCCA) :	437
mseI (TTAA) :	175 1788 1915 1981 2220 2361
mslI (CAYNNNRTG) :	400 1405 1407

mspAI (CMGCKG) :	568 1672
mspI (CCGG) :	139 361 684 996 1227 1239 1602 2128 2354 2367 2372
munI (CAATTG) :	1622
mvaI (CCWGG) :	528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
mvnI (CGCG) :	38 331 1329
mwOI (GCNNNNNNNGC) :	303 312 315 321 357 502 535 641 650 793 802 1555 1665
nciI (CCSGG) :	139 360 684 995 996 1239 1602 2353 2354
ndeII (GATC) :	271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937
	2183
nlaIII (CATG) :	32 199 336 555 1014 1075 1315 1407 1497
nlaIV (GGNNCC) :	270 532 533 558 640 705 991 1054 1140 1164 1295 1609 1741 1985 2374
notI (GCGGCCGC) :	2326
nspBII (CMGCKG) :	568 1672
nspHI (RCATGY) :	31 335
nspI (RCATGY) :	31 335
paer7I (CTCGAG) :	62
pali (GGCC) :	438 501 534 543 612 658 769 1366 1776 2328
pflFI (GACNNNGTC) :	451
pleI (GAGTCNNNN) :	204 451 585 1120 1500 2407
ppuMI (RGGWCCY) :	558 1984 2142
pshAI (GACNNNGTC) :	553
pspAI (CCCGGG) :	995 2353
pspGI (CCWGG) :	528 609 813 882 1038 1113 1137 1144 1342 1363 1638 2061
pspOMI (GGGCCC) :	533
pstI (CTGCAG) :	520 2379
pvuII (CAGCTG) :	568
rcal (TCATGA) :	1074
rmaI (CTAG) :	243 1210 1216 1396 1504 1805 1849 1889 2140 2337
rsaI (GTAC) :	41 387 1296 1897 2375 2387
rsrII (CGGWCCG) :	2368

sacI (GAGCTC) :	484 2342
salI (GTCGAC) :	2348
sapI (GCTCTTCNNNN) :	15 486 1099
sau3AI (GATC) :	271 628 786 823 960 1090 1320 1566 1599 1610 1644 1812 1817 1937
	2183
sau96I (GGNCC) :	533 534 559 705 769 909 1140 1776 1985 2143 2369
sbfi (CTGCGAGG) :	2378
scrFI (CCNGG) :	139 360 528 609 684 813 882 995 996 1038 1113 1137 1144 1239 1342
	1363 1602 1638 2061 2353 2354
	1067
sfaNI (GCATC) :	10 520 2379 2400
sfcI (CTRYAG) :	534
sfiI (GGCCNNNNNGGCC) :	995 2353
smaI (CCCGGG) :	62 2006 2147
smlI (CTYRAG) :	42
snaBI (TACGTA) :	2336
speI (ACTAGT) :	31
sphI (GCATGC) :	40
splI (CGTACG) :	2378
sse8387I (CCTGCAGG) :	1528 1949
sspI (AATATT) :	484 2342
sstI (GAGCTC) :	26 43 149 668
taiI (ACGT) :	63 443 1259 1322 2349
taqI (TCGA) :	914 1148 1275 1829 2070
tfiI (GAWTC) :	38 331 1329
thai (CGCG) :	62
tliI (CTCGAG) :	175 1788 1915 1981 2220 2361
tru9I (TTAA) :	292 312 315 318 321 508 519 522 567 570 672 1235 1552 1756 2017 2024
tseI (GCWGC) :	4 180 1435 2158
tsp45I (GTSAC) :	55 410 842 942 1250 1382 1623 1668 1748 1880 2107 2359 2363
tsp509I (AATT) :	

[illegible]

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.